Pages that link to "Q33899616"
Jump to navigation
Jump to search
The following pages link to The cytomegalovirus-"safe" blood product: is leukoreduction equivalent to antibody screening? (Q33899616):
Displaying 13 items.
- High incidence of Epstein-Barr virus, cytomegalovirus and human herpesvirus 6 infections in children with cancer (Q24800206) (← links)
- Universal WBC reduction: the case for and against (Q34247853) (← links)
- Evidence-based recommendations for the use of WBC-reduced cellular blood components (Q34405086) (← links)
- Risks associated with transfusion of cellular blood components in canada (Q35122220) (← links)
- Utilization management in the blood transfusion service (Q35492937) (← links)
- Seroprevalence of cytomegalovirus among some voluntary blood donors at the 37 military hospital, accra, ghana. (Q35623186) (← links)
- Why implement universal leukoreduction? (Q37671773) (← links)
- Defining the risks for cytomegalovirus infection and disease after solid organ transplantation (Q37680941) (← links)
- Cytomegalovirus transmission in pediatric renal transplant recipients during the window period (Q40862316) (← links)
- Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products (Q41640997) (← links)
- Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors (Q42275032) (← links)
- The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center (Q44218602) (← links)
- Risk of cytomegalovirus transmission by blood products after solid organ transplantation. (Q64958118) (← links)